MedTrace Logo

38 Week Extension Study to CAIN457C2303

NCT01093846 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2016-02-22

Study results available
· View outcomes & findings →

Summary

A 38-week extension to a 24 week multicenter, randomized, double-masked, placebo controlled study to assess the difference in the rate of recurrent exacerbations in Behçet's patients with posterior or panuveitis treated with AIN457 vs placebo adjunctive to standard-of-care immunosuppressive therapy

Conditions

  • Uveitis

Interventions

DRUG

AIN457

300mg every 4 weeks

DRUG

AIN457

300mg every 2 weeks

DRUG

Placebo AIN457

Placebo to AIN457

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States
  • Egypt
  • France
  • Germany
  • Greece
  • Hong Kong
  • Israel
  • Jordan
  • Singapore
  • South Korea
  • Spain
  • Taiwan
  • Tunisia
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01093846 on ClinicalTrials.gov